Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

T-DM1

- PMLiVE

Tavros Therapeutics and Vividion Therapeutics collaborate in oncology programmes

Tavros will receive $17.5m in a cash upfront payment from Vividion, according to the deal

- PMLiVE

Pfizer’s Talzenna combination treatment meets primary endpoint in phase 3 prostate cancer study

An improvement in radiographic progression-free survival was demonstrated

- PMLiVE

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment

Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?

Say Communications

- PMLiVE

Roche announces launch of HPV self-sampling solution for cervical cancer screening

Around 342,000 die from cervical cancer worldwide, despite it being a preventable disease

- PMLiVE

Lilly’s Retevmo approved by FDA for RET fusion+ advanced/metastatic solid tumours

Results demonstrated an overall response rate of 44% across multiple tumour types

- PMLiVE

University of Cambridge launches Early Cancer Institute for complex cancers

It is the first UK institute dedicated to identifying and researching early cancers

- PMLiVE

Roche’s Vabysmo receives EC approval to treat two leading causes of vision loss

60% of people treated with Vabysmo were able to extend treatment to every four months

- PMLiVE

WHO/Europe urges endorsement of cervical cancer elimination roadmap

The initiative aims to fully vaccinate 90% of girls with the HPV vaccine by age 15

- PMLiVE

AstraZeneca’s Imfinzi plus chemotherapy shows promise for advanced biliary tract cancer

Updated results from a phase 3 trial showed the combination treatment reduced the risk of death by 24% versus chemotherapy alone

- PMLiVE

Novartis and BeiGene announce positive phase 3 trial results for hepatocellular carcinoma treatment

Hepatocellular carcinoma accounts for 75-85% of liver cancer diagnoses

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Enhertu shows significant improvements for lung cancer patients

Data showed a confirmed objective response rate of 53.8% in patients with HER2-mutant metastatic non-small cell lung cancer

- PMLiVE

AstraZeneca shares positive Tagrisso data in patients with EGFR-mutated lung cancer

Lung cancer is the leading cause of cancer death among both men and women

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links